Anogenital Warts (HPV)

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Anogenital warts (HPV) are small growths that appear on the skin or mucous membranes around the genital and anal areas. They are caused by an infection with the human papillomavirus (HPV), which affects the skin and mucous membranes. These warts can vary in size and shape, often appearing as soft, flesh-colored bumps or cauliflower-like clusters. The condition primarily involves the skin and mucosal surfaces of the anogenital region. While usually painless, the warts can cause discomfort, itching, or bleeding. The infection is spread through sexual contact, making it a common sexually transmitted condition. The presence of these warts can affect a person's quality of life and may require medical evaluation.

Clinical Definition

Anogenital warts (condylomata acuminata) are benign epithelial growths, about 90% caused by nononcogenic HPV6/11. Basal keratinocyte infection produces flat, papular, pedunculated or verrucous lesions. They may recur after treatment. High-risk HPV can coexist, but typical low-risk warts are not the usual precursors of anogenital cancer. Transmission can occur without visible warts.

Inciting Event

  • Sexual contact with an HPV-infected partner is the primary inciting event.

  • Microabrasions in the anogenital mucosa facilitate viral entry into basal keratinocytes.

Latency Period

  • Warts may appear months or years after acquisition; their appearance cannot reliably date infection or identify the transmitting partner.

  • Some infections remain subclinical or latent for years before lesion development.

Diagnostic Delay

  • Warts may be misdiagnosed as other anogenital lesions such as molluscum contagiosum or seborrheic keratosis.

  • Patients may delay seeking care due to asymptomatic or minimally symptomatic lesions.

  • Lack of awareness about HPV-related lesions can lead to missed diagnosis by clinicians.

Clinical Presentation


Signs & Symptoms

  • Asymptomatic in many cases, with warts discovered incidentally during exam.

  • Pruritus or mild discomfort localized to the wart area.

  • Bleeding or irritation if lesions are traumatized or inflamed.

  • Occasional pain if warts become large or ulcerated.

  • Psychosocial distress due to cosmetic concerns or stigma.

History of Present Illness

  • Patients report painless, flesh-colored or verrucous papules in the anogenital area that may coalesce into larger plaques.

  • Lesions often have a gradual onset and slow progression over weeks to months.

  • Some patients experience pruritus, bleeding, or discomfort especially if lesions are traumatized.

Past Medical History

  • History of prior HPV infection or anogenital warts increases risk of recurrence.

  • Immunosuppressive conditions such as HIV/AIDS or organ transplantation are relevant.

  • Lack of prior HPV vaccination is a notable risk factor.

Family History

  • There is no significant hereditary pattern for anogenital warts as HPV infection is acquired.

  • Family sexual behavior is not a diagnostic risk marker. Use a respectful individual exposure and immune-status history; infection can remain unrecognized for years.

Physical Exam Findings

  • Multiple flesh-colored, verrucous papules or plaques localized to the anogenital region.

  • Lesions often have a cauliflower-like surface and may coalesce into larger masses.

  • Warts are typically non-tender but can be friable and bleed if traumatized.

  • Lesions may be found on the penis, vulva, perianal skin, or cervix depending on exposure.

  • Occasionally, urethral or vaginal warts can be visualized on careful examination.

Diagnostic Workup


Diagnostic Criteria

Usually diagnose by visual inspection. Biopsy lesions that are pigmented, indurated, fixed, ulcerated or bleeding, or when diagnosis is uncertain, treatment fails or disease worsens, especially with immunosuppression. Histology can show koilocytes and papillomatosis. HPV typing/PCR and routine acetic-acid testing are not recommended for diagnosing warts.

Pathophysiology


Key Mechanisms

  • Low-risk HPV 6 and 11 infect basal keratinocytes through epithelial microinjury. Viral DNA is generally maintained episomally, with differentiation-linked replication and epithelial proliferation. Integration is not required for wart formation; high-risk HPV oncogenesis is a distinct process.

  • Epithelial hyperplasia results in the formation of characteristic exophytic, papillomatous lesions in the anogenital region.

  • Immune evasion by HPV allows persistent infection and lesion growth due to limited local immune response activation.

  • Koilocytosis (perinuclear clearing and nuclear atypia) in infected epithelial cells is a hallmark of HPV cytopathic effect.

InvolvementDetails
Organs

Anus is a common site for HPV-induced wart formation due to mucocutaneous junction susceptibility

External genitalia including vulva, penis, and perineum are frequently affected by anogenital warts

Tissues

Epithelial tissue of the anogenital region is the site of HPV infection and wart development

Stratified squamous epithelium undergoes hyperplasia and papillomatosis in wart lesions

Cells

Keratinocytes are the primary infected cells by HPV leading to wart formation through viral replication

Langerhans cells participate in antigen presentation and local immune response against HPV-infected cells

CD8+ T cells mediate cytotoxic immune clearance of HPV-infected keratinocytes

Chemical Mediators

Interferon-alpha is produced locally to enhance antiviral immunity against HPV

Tumor necrosis factor-alpha (TNF-α) contributes to inflammation and wart regression

Interleukin-12 (IL-12) promotes Th1 immune response critical for viral clearance

Treatments


Pharmacological Treatments

  • Imiquimod

    • Mechanism:
      • Stimulates local immune response via TLR7 agonism to enhance antiviral activity against HPV-infected cells

    • Side effects:
      • Local skin irritation

      • Erythema

      • Pruritus

    • Clinical role:
      • Patient-applied option for accessible external warts; select with the clinician according to site and tolerance. Avoid during pregnancy pending better safety data.

  • Podophyllotoxin

    • Mechanism:
      • Inhibits microtubule assembly causing mitotic arrest and necrosis of wart tissue

    • Side effects:
      • Local irritation

      • Ulceration

      • Pain

    • Clinical role:
      • Patient-applied podofilox/podophyllotoxin for appropriate external lesions; do not use during pregnancy or on unapproved internal sites. Distinct from podophyllin resin.

  • Sinecatechins

    • Mechanism:
      • Green-tea catechin preparation; the precise mechanism responsible for wart clearance is unknown.

    • Side effects:
      • Local erythema

      • Pruritus

      • Burning sensation

    • Clinical role:
      • Patient-applied option for external genital/perianal warts in immunocompetent adults; not inherently a universal second-line treatment.

  • Trichloroacetic acid (TCA)

    • Mechanism:
      • Caustic agent causing chemical coagulation and destruction of wart tissue

    • Side effects:
      • Local pain

      • Ulceration

      • Scarring

    • Clinical role:
      • Clinician-applied destructive option; protect surrounding tissue from chemical burns. Appropriate for selected sites and can be used in pregnancy.

Non-pharmacological Treatments

  • Clinician-delivered cryotherapy destroys warts. Observation is also reasonable for selected typical asymptomatic lesions because spontaneous regression can occur.

  • Surgical excision for large or refractory warts to physically remove lesions

  • Laser ablation may treat extensive/refractory lesions; use trained operators, appropriate eye protection and local smoke evacuation.

  • Electrocautery to destroy warts by thermal coagulation

Prevention


Pharmacological Prevention

  • The US 9-valent HPV vaccine includes wart-associated types 6/11 and oncogenic types 16/18/31/33/45/52/58. It prevents new infections, not existing warts.

  • Routine vaccination is at 11–12 years, may start at 9, with catch-up through 26; ages 27–45 use shared decision-making. Usually two doses if started before 15, three if started later or immunocompromised. Defer remaining doses during pregnancy.

  • No antiviral medications currently prevent initial HPV infection.

Non-pharmacological Prevention

  • Consistent condom use reduces but does not eliminate HPV transmission risk.

  • Limiting number of sexual partners decreases exposure to HPV.

  • Follow applicable cervical cancer screening recommendations; external genital warts alone do not require more frequent screening. Screening does not prevent acquisition of wart-causing HPV.

  • Education on safe sexual practices to reduce HPV and other STI transmission.

Outcome & Complications


Complications

  • Secondary bacterial infection of warts due to excoriation or trauma.

  • Ordinary HPV6/11 warts are benign and not usual cancer precursors. High-risk HPV coinfection or a lesion mimicking a wart may contain HSIL/cancer; biopsy suspicious lesions.

  • Obstruction of the urethra or anal canal by large wart masses.

  • Psychological impact including anxiety and reduced quality of life.

Short-term Sequelae Long-term Sequelae
  • Wart growth and spread to adjacent anogenital skin areas.

  • Local inflammation causing erythema and tenderness.

  • Recurrence after treatment due to viral persistence in basal epithelium.

  • Warts may regress, persist or recur; removing visible lesions does not reliably eradicate HPV or establish that transmission is no longer possible.

  • Cancer risk relates chiefly to persistent oncogenic HPV, not routine transformation of a typical low-risk wart. Continue indicated cancer screening and evaluate atypical lesions.

  • Scarring or pigmentary changes after repeated treatments or large lesions.

  • Persistent psychosocial distress related to chronic disease and stigma.

Differential Diagnoses


Anogenital Warts (HPV) versus Condyloma lata (secondary syphilis)

Anogenital Warts (HPV)

Condyloma lata (secondary syphilis)

Raised, verrucous, flesh-colored papules or plaques

Flat, broad, moist, grayish plaques

Caused by human papillomavirus (HPV), mainly types 6 and 11

Caused by Treponema pallidum

Typical lesions are diagnosed visually; biopsy atypical/uncertain lesions. Routine wart HPV PCR is not recommended.

Positive non-treponemal and treponemal serologic tests

Anogenital Warts (HPV) versus Molluscum contagiosum

Anogenital Warts (HPV)

Molluscum contagiosum

Larger, cauliflower-like, verrucous papules without central umbilication

Small, dome-shaped, pearly papules with central umbilication

Caused by human papillomavirus (HPV)

Caused by molluscum contagiosum virus (poxvirus)

Common in sexually active adults

Common in children; genital molluscum also occurs in sexually active immunocompetent adults and can be extensive with immunosuppression.

Anogenital Warts (HPV) versus Herpes simplex virus (HSV) infection

Anogenital Warts (HPV)

Herpes simplex virus (HSV) infection

Painless, verrucous papules or plaques

Painful grouped vesicles on an erythematous base

Chronic, slowly growing warty lesions

Recurrent painful outbreaks with vesicles and ulcers

Visual diagnosis, with histology when indicated; HPV PCR is not routine.

HSV NAAT/PCR from an active lesion is preferred when available; culture is less sensitive, particularly as lesions heal.

Anogenital Warts (HPV) versus Lichen planus

Anogenital Warts (HPV)

Lichen planus

Flesh-colored, verrucous papules without Wickham striae

Flat-topped, violaceous, polygonal papules with Wickham striae

Viral-induced epithelial proliferation

T-cell mediated autoimmune reaction

Histopathology shows koilocytosis and papillomatosis

Lichenoid, band-like lymphocytic inflammation at the dermoepidermal junction with basal injury and saw-tooth rete ridges.

Anogenital Warts (HPV) versus Bowenoid papulosis

Anogenital Warts (HPV)

Bowenoid papulosis

Flesh-colored, verrucous papules

Multiple reddish-brown papules with possible erosion

Histology shows koilocytosis without full-thickness atypia

Histology shows full-thickness epidermal atypia (carcinoma in situ)

Associated with low-risk HPV types (6, 11)

Associated with high-risk HPV types (16, 18)